A meta-analysis of 7 case–control studies of TGFBR1*6A and various cancer types combined showed that TGFBR1*6A carriers had a 26% increased risk.72 The role of TGFBR1*6A in pancreatic cancer remains unclear and is a subject of future study. This evidence concerns the gene TGFBR1 and familial pancreatic carcinoma.